touchIMMUNOLOGY touchIMMUNOLOGY
Dermatological Conditions

Christopher Griffiths, Dermatology Meeting News 2021: Guselkumab VOYAGE-1 Study

Copy Link
Published Online: Feb 8th 2022

It was an absolute pleasure to speak with Prof. Christopher Griffiths (University of Manchester, Manchester, UK) about recent developments in the treatment of psoriasis including the VOYAGE study. 

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  

Questions

  1. Could you tell us about the aims and design of the VOYAGE 1 study? (00:10-01:14)
  2. What has the study taught us about the efficacy and safety of guselkumab in psoriasis? (01:14-02:25)
  3. There are other novel IL-17/23 antagonists currently in development e.g. bimekizumab and mirikizumab, based on clinical data to date, which are you most excited/optimistic about? (02:25-03:42)

Disclosures: Christopher Griffiths has the following disclosures: AbbVie  – (AD Board, Grant Holder), Almirall (Advisor), Amgen (Advisor), BMS (Speaker, Grant Holder) , Boehringer Ingelheim (Ad Board / Advisor), Celgene  – (Ad Board / Speaker) , Galderma – (AD Board, Grant Holder) , Janssen – (Speaker, Grant holder) , LEO Pharma (Grant Holder / Speaker) , Lilly – (Grant Holder / Ad Board) , MSD (Advisor), Novartis (Ad Board / Speaker / Ad Board), Pfizer – (Grant Holder, Speaker) , Sandoz  (Grant Holder) and UCB Pharma – (AD Board)

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.

Related Videos In Dermatological Conditions
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72